Letter by Mead et al Regarding Article, 'Selective Serotonin Reuptake Inhibitors for Stroke: More Trials are Needed'
| Autor: | Martin Dennis, Erik Lundström, Veronica Murray, Graeme J. Hankey, Maree L. Hackett, Gillian Mead |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Advanced and Specialized Nursing
Fluoxetine 20 MG medicine.medical_specialty Fluoxetine business.industry medicine.medical_treatment Serotonin reuptake medicine.disease behavioral disciplines and activities Physical medicine and rehabilitation Modified Rankin Scale mental disorders Ischaemic stroke medicine Motor recovery Neurology (clinical) Cardiology and Cardiovascular Medicine business Stroke recovery Psychiatry Stroke medicine.drug |
| Zdroj: | Stroke. 44 |
| ISSN: | 1524-4628 0039-2499 |
| Popis: | To the Editor: We read with interest the recent Controversies in Stroke, in which 2 authors, Drs Marshall and Chollet, gave opposing views about whether selective serotonin reuptake inhibitors (SSRI) should be given routinely to people with stroke.1,2 Drs Marshall and Chollet both cite the Fluoxetine for Motor Recovery After Ischaemic Stroke (FLAME) trial, in which fluoxetine 20 mg daily given to 118 patients with motor deficits, who were not depressed, improved motor recovery and reduced disability measured with the modified Rankin scale at 3 months.3 A third author team reflected on the views expressed by Drs Chollet and Marshall and recommended the use of SSRI on a patient-by-patient basis, but taking particular account of their mood.4 Our Cochrane review of SSRI for stroke recovery identified 52 trials of SSRI in stroke recruiting 4059 patients.5 Twenty-eight of the trials used fluoxetine. Our meta-analyses demonstrated that at the … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|